CAR-T therapy for adults with certain blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a type of immunotherapy called CAR-T cells that target two proteins (CD19 and CD22) on cancer cells. It may be an option for adults with B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) that has come back or not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have B-cell ALL or B-cell NHL that has relapsed (come back) or is refractory (not responding) after at least one prior treatment.
- You are in reasonably good health for your age, with a life expectancy of at least 12 weeks.
- You have not received certain chemotherapy drugs (like bendamustine or fludarabine) or specific other treatments recently.
- You do not have a current serious infection, such as active hepatitis B or C, or uncontrolled other infections.
- You do not have severe heart problems, recent stroke, or other major organ issues that are not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma that has come back or did not respond to previous treatments.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.